Targeting Prolactin Receptor (PRLR) Signaling in PRLR-Positive Breast and Prostate Cancer

In this issue of The Oncologist, Agarwal et al. report negative results from a phase I trial of LFA102. Although “negative” in terms of antitumor activity, the study provides useful pharmacokinetic and pharmacodynamic information. Future trials evaluating PRLR blockers alone and in combination with...

Full description

Saved in:
Bibliographic Details
Published in:Oncologist
Main Authors: O’Sullivan, Ciara C., Bates, Susan E.
Format: Artigo
Language:Inglês
Published: AlphaMed Press 2016
Subjects:
Commentary
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4861375/
https://ncbi.nlm.nih.gov/pubmed/27107001
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0108
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items